COSCIENS Biopharma Total Liab Over Time
| CSCI Stock | 2.85 0.19 7.14% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out COSCIENS Biopharma Performance and COSCIENS Biopharma Correlation. COSCIENS |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of COSCIENS Biopharma. If investors know COSCIENS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.69) | Revenue Per Share 3.759 | Quarterly Revenue Growth 0.041 | Return On Assets (0.23) | Return On Equity (0.66) |
The market value of COSCIENS Biopharma is measured differently than its book value, which is the value of COSCIENS that is recorded on the company's balance sheet. Investors also form their own opinion of COSCIENS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is COSCIENS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because COSCIENS Biopharma's market value can be influenced by many factors that don't directly affect COSCIENS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between COSCIENS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if COSCIENS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, COSCIENS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Liab Analysis
Compare COSCIENS Biopharma and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Total Liab Over Time
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EQ | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 2.2 M | 13.7 M | 15.6 M | 18.9 M | 46.5 M | 28 M | 21.1 M |
| DMAC | 1.3 M | 364.6 K | 1.6 M | 1.5 M | 1.8 M | 1.5 M | 627 K | 1 M | 1.3 M | 1.4 M | 2.1 M | 1.5 M | 2.6 M | 3.1 M | 3.3 M |
| VALN | 9.8 M | 32.6 M | 27.5 M | 110.3 M | 103.1 M | 130.9 M | 106.8 M | 96.7 M | 86.7 M | 129.6 M | 371.7 M | 646.8 M | 401.5 M | 331.8 M | 348.4 M |
| VANI | 11 M | 11 M | 11 M | 21.9 M | 8.5 M | 8 M | 5.7 M | 6.6 M | 7.6 M | 9.3 M | 3.3 M | 3 M | 6.8 M | 25 M | 26.3 M |
| DNLI | 52.3 M | 52.3 M | 52.3 M | 52.3 M | 52.3 M | 52.3 M | 16.5 M | 20.9 M | 115.1 M | 158.3 M | 453.7 M | 441.9 M | 417.8 M | 123 M | 220 M |
| DNTH | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 4.1 M | 11.7 M | 20.3 M | 17.7 M | 26.7 M | 127.5 M | 10.5 M | 10 M |
| DOMH | 1.6 M | 940.4 K | 3.9 M | 21.6 M | 7.6 M | 4.9 M | 6 M | 4.9 M | 1.2 M | 750 K | 877 K | 1.1 M | 2.5 M | 4.6 M | 4.5 M |
| VCEL | 36.1 M | 20.7 M | 5.7 M | 5.3 M | 11.9 M | 12.2 M | 23.9 M | 32 M | 16.5 M | 42.1 M | 71.3 M | 73.2 M | 80.7 M | 127.7 M | 134.1 M |
| VCNX | 6.2 M | 6.2 M | 6.2 M | 6.2 M | 6.2 M | 6.2 M | 6.2 M | 7.3 M | 6.7 M | 6.9 M | 14.3 M | 2.4 M | 2.8 M | 5.9 M | 5.3 M |
| VCYT | 1.9 M | 1.9 M | 14.2 M | 23.2 M | 23.5 M | 24 M | 41.5 M | 41.4 M | 40.9 M | 35.8 M | 35.9 M | 91.3 M | 81.2 M | 70.8 M | 44.5 M |
COSCIENS Biopharma and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Total Liab description
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.My Equities
My Current Equities and Potential Positions
| COSCIENS Biopharma | CSCI |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Quebec; Canada |
| Exchange | NASDAQ Exchange |
null 2.85
Check out COSCIENS Biopharma Performance and COSCIENS Biopharma Correlation. For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
COSCIENS Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.